RevBio has received a $2 million grant to fund the preclinical development of a bone graft that will release locally acting nonopioid pain medication.
Its bone graft candidate, Tetranite, would be used to fill extraction sites and mitigate postoperative pain following wisdom teeth removal. Also, the material will occlude the socket and reduce the potential for dry socket.
The U.S. National Institutes of Health (NIH) awarded the grant via its Helping to End Addiction Long-term Initiative, which aims to improve strategies for the prevention and treatment of opioid misuse and addiction. This grant complements funding that RevBio received from the NIH-funded Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center and a grant from the National Institute of Dental and Craniofacial Research.
